BioGaia AB: Year-end report January – December 2024
FOURTH QUARTER 2024 (Figures in parentheses refer to the corresponding period last year, unless otherwise specified). · Net sales amounted to...
Read moreInvitation to media and analyst briefing for BioGaia Q4 2024 report
BioGaia's (NASDAQ: BIOG) financial report for the fourth quarter of 2024 will be published at approximately 8:00 AM...
Read moreBioGaia terminates the distribution contract with its partner in France to take the business direct
In line with its long-term strategy to market and sell its product through own subsidiaries in certain prioritized markets,...
Read moreBioGaia launches a new probiotic supplement, BioGaia® Gastrus® PURE ACTION, designed for people with sensitive digestive systems
We are proud to launch BioGaia® Gastrus® PURE ACTION, a clean ingredient, double-strength, FODMAP-friendly probiotic designed to support...
Read moreAs World AMR Awareness Week 2024 comes to a close, BioGaia continues to highlight the important role of probiotics in combating antibiotic resistance
Antibiotic resistance is among the most pressing global health threats today. According to the World Health Organization (WHO), approximately 1....
Read moreAnatom Holding acquires 4.9% shareholding in BioGaia
BioGaia AB (NASDAQ: BIOG) announces that Anatom Holding AG, a Switzerland-based investment firm, has acquired 4,979,813 class...
Read moreBioGaia AB: Interim Management Statement January – September 2024
THIRD QUARTER 2024 (For balance sheet items, figures in parentheses refer to year-end 2023 figures. For income statement and...
Read more